DxNA, PathoGene deal

DxNA will acquire exclusive rights for unit dose platform applications of PathoGene's next-generation multiplexed Staphylococcus MRSA-positive assay for use on DxNA's real-time PCR GeneSTAT platform. PathoGene will receive an upfront payment and is eligible for milestones and royalties. PathoGene's assay provides rapid identification and drug resistance information for Staphylococcus infections, including methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug-resistant, coagulase-negative Staphylococcus strains. ...